Gilead Sciences, Inc. (GILD) Shares Bought by Hennessy Advisors Inc.

Hennessy Advisors Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.1% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 30,300 shares of the biopharmaceutical company’s stock after acquiring an additional 1,200 shares during the quarter. Hennessy Advisors Inc.’s holdings in Gilead Sciences were worth $2,455,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Keel Point LLC boosted its position in shares of Gilead Sciences by 0.4% during the 2nd quarter. Keel Point LLC now owns 3,123 shares of the biopharmaceutical company’s stock valued at $221,000 after acquiring an additional 12 shares during the last quarter. Paradigm Financial Advisors LLC lifted its position in Gilead Sciences by 0.3% in the 2nd quarter. Paradigm Financial Advisors LLC now owns 8,723 shares of the biopharmaceutical company’s stock worth $617,000 after buying an additional 26 shares during the last quarter. West Oak Capital LLC lifted its position in Gilead Sciences by 0.7% in the 2nd quarter. West Oak Capital LLC now owns 4,666 shares of the biopharmaceutical company’s stock worth $330,000 after buying an additional 32 shares during the last quarter. First Heartland Consultants Inc. lifted its position in Gilead Sciences by 0.4% in the 2nd quarter. First Heartland Consultants Inc. now owns 8,927 shares of the biopharmaceutical company’s stock worth $632,000 after buying an additional 39 shares during the last quarter. Finally, Princeton Portfolio Strategies Group LLC lifted its position in Gilead Sciences by 0.4% in the 2nd quarter. Princeton Portfolio Strategies Group LLC now owns 9,766 shares of the biopharmaceutical company’s stock worth $691,000 after buying an additional 41 shares during the last quarter. Hedge funds and other institutional investors own 75.94% of the company’s stock.

Shares of Gilead Sciences, Inc. (GILD) opened at $78.10 on Wednesday. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $86.27. The firm has a market capitalization of $101,990.00, a P/E ratio of 8.89, a price-to-earnings-growth ratio of -1.58 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The firm had revenue of $6.51 billion during the quarter, compared to the consensus estimate of $6.40 billion. During the same quarter in the previous year, the company posted $2.75 earnings per share. The business’s revenue was down 13.2% on a year-over-year basis. equities research analysts forecast that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Shareholders of record on Friday, December 15th were given a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 annualized dividend and a yield of 2.66%. Gilead Sciences’s payout ratio is currently 23.66%.

In other news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Gregg H. Alton sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the transaction, the executive vice president now directly owns 77,363 shares in the company, valued at $5,788,299.66. The disclosure for this sale can be found here. Insiders have sold 461,666 shares of company stock worth $34,072,567 over the last three months. Insiders own 1.30% of the company’s stock.

GILD has been the subject of a number of recent research reports. Vetr upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $91.98 target price for the company in a research report on Friday, October 13th. Berenberg Bank set a $96.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Thursday, October 19th. BMO Capital Markets dropped their target price on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research report on Friday, October 27th. Credit Suisse Group restated a “buy” rating and issued a $82.00 target price on shares of Gilead Sciences in a research report on Thursday, December 7th. Finally, Mizuho boosted their target price on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research report on Wednesday, November 8th. Two analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $85.03.

COPYRIGHT VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Bought by Hennessy Advisors Inc.” was originally reported by Markets Daily and is the property of of Markets Daily. If you are viewing this article on another publication, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The legal version of this article can be viewed at https://www.themarketsdaily.com/2018/01/10/gilead-sciences-inc-gild-shares-bought-by-hennessy-advisors-inc.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply